Samsung Biologics Recognized as a Global Leader in Water Security with CDP ‘A’ Rating
Samsung Biologics, a premier contract development and manufacturing organization (CDMO) in the biopharmaceutical sector, has been recognized for its outstanding environmental stewardship by the Carbon Disclosure Project (CDP), receiving an ‘A’ rating in Water Security. This achievement marks a significant milestone for the company, highlighting its commitment to sustainable business practices, responsible water management, and alignment with global environmental standards.
Two years into its participation in CDP assessments, Samsung Biologics has advanced to the top tier in Water Security, securing a rating higher than the previous year. The CDP ‘A List’ honors companies that demonstrate exceptional leadership in environmental performance and transparency, signifying global recognition for organizations that take robust, measurable action to protect natural resources. Notably, only approximately 2% of companies assessed by CDP achieve this elite designation, underscoring the significance of Samsung Biologics’ accomplishment.
Founded in 2000, the Carbon Disclosure Project has become a leading platform for environmental reporting, inviting major global companies to disclose detailed information about their environmental impact, climate strategy, and sustainability initiatives. Participation in CDP assessments has grown increasingly important for businesses operating in sectors with significant environmental footprints, including pharmaceuticals, energy, and manufacturing. Leading pharmaceutical companies, in particular, actively encourage their partners and suppliers to engage in CDP reporting, as it provides a standardized and transparent method for tracking progress in critical areas such as climate action, water stewardship, and natural capital management.
Achieving a top rating from CDP is not merely a symbolic accolade; it represents rigorous external validation of a company’s sustainability performance. CDP assessments evaluate a broad spectrum of factors, including strategy, governance, implementation, and reporting accuracy. Companies must demonstrate measurable progress in reducing environmental risks and impacts, establishing clear targets, and maintaining high standards of accountability. By earning an ‘A’ rating in Water Security, Samsung Biologics has confirmed that its water management policies and practices meet the highest international benchmarks.
In this year’s assessment, CDP recognized Samsung Biologics for its comprehensive and forward-looking approach to water stewardship. The company has set concrete goals across several key areas, including natural capital strategies, water pollution control, and the optimization of water reuse rates. By focusing on these areas, Samsung Biologics not only mitigates environmental risks but also strengthens operational resilience in a sector where water is a critical input for manufacturing processes. The company’s reporting demonstrated a high degree of accuracy and reliability in tracking water intake, discharge, and overall consumption, further reinforcing its credibility in the eyes of global sustainability evaluators.
John Rim, CEO and President of Samsung Biologics, emphasized the broader significance of the recognition, stating, “This achievement reflects our ongoing commitment to the ESG strategies embraced by our clients worldwide. We understand that environmental responsibility is not just a regulatory requirement but a strategic imperative that aligns with the expectations of our partners, stakeholders, and the communities in which we operate. Moving forward, we will continue to pursue carbon neutrality and enhance water resource management across all levels of our operations.”
Samsung Biologics’ recognition by CDP aligns with its broader environmental, social, and governance (ESG) initiatives. As the chair of the Supply Chains Working Group within the Sustainable Markets Initiative (SMI) Health Systems Task Force, the company plays an active role in promoting industry-wide sustainability standards. Through this leadership position, Samsung Biologics not only implements best practices internally but also encourages other organizations within the biopharmaceutical supply chain to adopt responsible environmental practices, further amplifying its impact on global sustainability efforts.
A central component of Samsung Biologics’ ESG strategy is its long-term commitment to achieving full carbon neutrality. The company has set ambitious goals to transition entirely to renewable energy sources by 2050, demonstrating a proactive approach to mitigating climate change. In parallel, Samsung Biologics continues to invest in technologies and practices that optimize natural capital use, reduce waste, and minimize water consumption. These initiatives include advanced water recycling systems, pollution reduction programs, and continuous monitoring of water quality and usage across manufacturing sites. By integrating sustainability into operational planning, the company strengthens both its environmental and economic resilience, ensuring that resource efficiency contributes to long-term business performance.
Water management, in particular, is a critical focus for Samsung Biologics due to the water-intensive nature of biopharmaceutical manufacturing. Maintaining high standards of water stewardship is essential not only for regulatory compliance but also for protecting ecosystems and supporting community water needs. The company’s initiatives demonstrate a holistic understanding of water as a shared resource, emphasizing both operational efficiency and environmental responsibility. By achieving an ‘A’ rating from CDP, Samsung Biologics positions itself among a select group of global companies that serve as benchmarks for sustainable water management practices.
The recognition also carries implications for Samsung Biologics’ clients and partners. In the pharmaceutical and biotechnology sectors, environmental performance is increasingly a factor in supplier selection and partnership agreements. Companies that can demonstrate rigorous sustainability practices, transparent reporting, and leadership in ESG metrics are better positioned to meet the expectations of multinational clients who prioritize sustainable supply chains. Samsung Biologics’ CDP recognition thus reinforces its status as a trusted, forward-looking CDMO partner capable of supporting clients’ own ESG objectives.
Beyond operational impacts, Samsung Biologics’ commitment to water security reflects a broader corporate philosophy of responsibility and innovation. The company integrates ESG considerations into strategic decision-making, ensuring that sustainability is not a peripheral concern but a central component of growth and competitiveness. Investments in environmentally friendly technologies, such as energy-efficient manufacturing systems and water reuse processes, exemplify this approach, delivering measurable benefits for both the company and the broader community.
Looking ahead, Samsung Biologics aims to continue building on this recognition by further enhancing its environmental programs and expanding its role as an industry leader in sustainability. Future initiatives are expected to focus on scaling renewable energy adoption, advancing circular economy practices, and deepening collaboration with partners and stakeholders to drive systemic improvements in water management and climate action. Through these efforts, the company seeks to maintain its position at the forefront of global ESG performance while contributing meaningfully to the collective challenge of environmental stewardship.
In conclusion, Samsung Biologics’ attainment of an ‘A’ rating from the Carbon Disclosure Project in Water Security represents a significant achievement that underscores the company’s leadership in sustainable manufacturing and responsible resource management. By demonstrating excellence in water stewardship, aligning with global ESG standards, and actively promoting sustainability across the biopharmaceutical industry, Samsung Biologics sets a benchmark for corporate environmental responsibility. As the company continues its journey toward carbon neutrality and enhanced natural capital management, this recognition reinforces its commitment to delivering not only high-quality biopharmaceutical solutions but also positive environmental and societal impact on a global scale.
Source link: https://samsungbiologics.com/
